Aviado · Research
Longevity Daily
Saturday, October 10, 2026
Listen
Today's Brief
Epigenetic reprogramming crossed a milestone this week: Life Biosciences presented the first human data from its Yamanaka-factor gene therapy trial. A UK Biobank cohort of 46,062 shows that higher VO2max cuts depression risk by 24%—the strongest prospective fitness-mental health link to date. In the lab, Bonn researchers reset the molecular clock of 80-year-olds' blood cells to under age 20. Our Aviado deep-dive explains why zinc supplementation reliably lowers CRP by ~1 mg/L and who benefits most.
10 stories3 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Fitter Heart, Calmer Mind: High Cardiorespiratory Fitness Cuts Depression Risk by 24%
In a UK Biobank prospective study of 46,062 adults followed for a median of 12.6 years, those with the highest objectively-measured VO2max had a 24% lower risk of developing depression and a 17% lower risk of anxiety compared to the least-fit quartile. The dose-response was linear for depression—more fitness, consistently lower risk—and the protection was strongest in people with lower biological age. Proteomic analysis identified seven candidate plasma proteins explaining the mechanism, including downregulated leptin (a metabolic stress marker) and upregulated neuroprotective factors SPINT3 and INSL3.
Read more →A Dementia Diagnosis Is No Longer Necessarily a Death Sentence
Emerging rehabilitation approaches are shifting how clinicians think about dementia—not just as irreversible terminal decline, but as a condition where function can sometimes be preserved or meaningfully improved. The 2025 World Alzheimer Report, co-led by researcher Jeon, was devoted entirely to rehabilitation, representing a paradigm shift for a field long focused on drug treatment alone. For the millions of people and families navigating a diagnosis, the message is cautiously hopeful: what happens after diagnosis may matter far more than previously assumed.
Read more →Supplements & Compounds
How Zinc Shuts Down Inflammatory Cascades — And Who Benefits Most
Zinc ions directly inhibit the NF-κB signaling pathway, suppressing production of pro-inflammatory cytokines like IL-6 and TNF-α—and the effect shows up clearly in bloodwork. Multiple meta-analyses of randomized controlled trials consistently find that zinc supplementation lowers high-sensitivity CRP by roughly 1 mg/L, with the largest gains concentrated in people with diabetes, obesity, or known zinc deficiency. Bioavailable forms (citrate, gluconate, aspartate) at 15–40 mg elemental zinc daily appear to be the practical sweet spot, though this analysis carefully lays out the gap between strong mechanistic evidence and what the human outcome data actually prove.
Read the full Aviado analysis →Beyond Blood Sugar: Do Diabetes Drugs Actually Slow Aging?
A narrative review maps how eight classes of glucose-lowering drugs—metformin, SGLT-2 inhibitors, GLP-1 receptor agonists, and five others—target the classical hallmarks of aging, framing type 2 diabetes as accelerated biological aging. Metformin has the broadest mechanistic evidence base; SGLT-2 inhibitors and GLP-1 agonists carry the strongest human longevity signals to date. The review is careful to distinguish mechanism (plentiful) from proven human outcome data (still limited)—essential reading for anyone already taking these drugs for off-label longevity purposes.
Read more →Research & Papers
Epigenetic Reprogramming Has Reached Its First Human Trial — and the Data Are Coming
Life Biosciences is presenting Phase 1 data from ER-100, a gene therapy that activates three Yamanaka factors (OCT4, SOX2, KLF4) inside the eye to restore function to damaged retinal ganglion cells. This marks the first time cellular reprogramming—the technology that routinely reverses aging hallmarks in mice—has been tested in humans, making it one of the most significant translational milestones in longevity medicine to date. The presentation at Eyecelerator (AAO 2026) focuses on safety and early efficacy signals in the eye; if the approach holds, it opens a rational path to applying reprogramming to other organs and tissues. Watch this space closely.
Read more →Scientists Reset 80-Year-Old Blood Cells to a Biological Age Under 20 — Then Converted Them Into Brain Cells
Researchers at the University of Bonn directly reprogrammed red blood cell precursors from elderly donors into induced neural stem cells—and in doing so, reset the epigenetic clocks of those cells to a biological age of under 20 years, per a study published in Aging Cell. The finding matters on two fronts: it demonstrates age-reversal is achievable in human cells (not just animal models), and it hints at a future where a patient's own blood could seed personalized cell therapies for neurodegenerative conditions. This is an in-vitro study; clinical translation remains years away.
Read more →A Single Drug Extended Lifespan Across Three Species by Directly Activating the Body's Master Energy Switch
MRC Laboratory of Medical Sciences researchers tested compound 991—a direct AMPK activator—in fission yeast, nematode worms, and fruit flies. All three species lived longer at the right dose, and the benefit vanished in strains engineered to lack AMPK, confirming on-target action. AMPK is the same energy-sensing enzyme that metformin partially activates via an indirect route; a drug that hits it directly clears a meaningful mechanistic hurdle on the path toward mammalian and eventually human lifespan trials.
Read more →Lifestyle & Nutrition
A New Blue Zone Has Been Identified in Sardinia — No Gym Required
Researchers have flagged Bolotana, a village in Sardinia, as a potential new blue zone, with women reaching 100 at rates that stand out even among the world's most long-lived populations. What's notable is the absence of structured exercise programs—centenarians here point to diet, tight social bonds, and the natural rhythms of traditional village life. The finding reinforces a growing body of evidence that built-in lifestyle habits, not formal health interventions, may be the most durable longevity prescription available.
Read more →Cutting One Ingredient From Processed Foods May Reduce Brain Fog, Anxiety, and Chronic Pain
Scientists studying low-glutamate diets report that reducing dietary glutamate—a flavor enhancer pervasive in processed foods—may significantly improve brain fog, chronic pain, and anxiety in certain individuals. One trial participant, a 68-year-old Army veteran who scored 40 on a PTSD scale (clinical threshold: 31–33), showed marked improvement after adopting the protocol. This is early, mechanistically interesting research rather than a dietary prescription—but the glutamate-neuroinflammation connection is biologically plausible and the trial data is intriguing enough to follow.
Read more →Industry & Policy
Big Pharma Is Now Betting Billions on Aging as a Drug Target
Longevity biotech companies raised approximately $3.74 billion in the first quarter of 2026 alone, as pharmaceutical executives who once dismissed aging research as speculative begin building dedicated pipelines. The shift signals that 'targeting aging itself' is crossing from fringe science into mainstream pharma strategy—with real capital allocations to match. For consumers, more investment means more clinical trials, more compounds moving through development, and eventually more approved options on the horizon.
Read more →